Chiromesh Therapeutics, Inc.

Chiromesh Therapeutics is a biotechnology company developing innovative solutions for localized, sustained drug delivery in solid tumors. The company’s lead platform, μMESH, is a conformable, micro-structured polymeric film designed to deliver advanced therapies directly at the diseased tissue. By adapting to complex anatomical sites and maintaining close contact with surrounding tissue, μMESH enables uniform, deep and prolonged drug exposure while minimizing systemic toxicity. μMESH is engineered from biodegradable, clinically established polymers and manufactured using scalable technologies. Its unique micro-structured architecture allows controlled, sustained release of a broad range of therapeutic agents, including small molecules, biologics (peptides, antibodies, oncolytic viruses), and nanomedicines, over weeks to months. Designed for use during surgical procedures, μMESH can be placed directly at the tumor surface or, post-resection, within the tumor cavity, bypassing biological barriers such as the blood-brain barrier and enabling localized combination therapies that are difficult to achieve with systemic treatments or other conventional implants (Gliadel wafer, injectable hydrogels). The company was founded by a multidisciplinary team with extensive expertise in biomaterials, translational oncology, neurosurgery, and company formation. Paolo Decuzzi, PhD (Co-founder, CEO & CSO), is a biomedical engineer and translational scientist with extensive experience developing advanced drug delivery platforms and building research and entrepreneurial programs in the US and Europe. Dean Felsher, MD, PhD (Co-founder, Scientific Advisor), leads the Translational Research and Applied Medicine program at Stanford and brings broad experience in oncology translation and biotechnology ventures. Frederick Lang, MD (Co-founder, Medical Advisor), is a clinical leader in neuro-oncology with extensive experience in brain tumor trials. Originally developed to address glioblastoma and brain and spine metastases, μMESH is being advanced toward clinical translation with an initial focus on neuro-oncology, while offering broader partnering opportunities across multiple therapeutic areas.